AVN-322
Chemical compound
- 1 min read
- 1 chapters
Related on Lably
Through Alzheimer's disease and Schizophrenia
The compound is a sister drug to AVN-101 and AVN-211, two similar compounds under trial for treating Alzheimer's. Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010. The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commence Phase II trials later the same year. The plan for further trials was discontinued in 2013.